Schaeffer's Top Stock Picks for '25

Analyst Downgrades: Twitter, American Int, Avalanche

Analyst Downgrades: Twitter, American International Group, and Avalanche Biotech

Jun 16, 2015 at 9:23 AM
facebook X logo linkedin


Analysts are weighing in today on social media concern Twitter Inc (NYSE:TWTR), insurance behemoth American International Group Inc (NYSE:AIG), and biopharmaceutical concern Avalanche Biotechnologies Inc (NASDAQ:AAVL). Here's a quick roundup of today's bearish brokerage notes on TWTR, AIG, and AAVL.

  • TWTR is down 1% ahead of the bell -- and could hit new annual lows for a second straight session -- as analysts apparently aren't excited by the company's recent front-office change. MKM Partners downgraded the stock to "neutral" from "buy" and reduced its price target by $18 to $39, saying it doesn't expect Twitter Inc's user growth woes to end anytime soon. TWTR is currently sitting in a 3.3% year-to-date hole, finishing yesterday at $34.67, and it could be hurt by additional bearish notes if it can't turn things around. Eleven of 25 brokerage firms with coverage on the shares maintain "strong buy" endorsements, while their average 12-month price target sits at $47.35 -- a 36.6% premium to current levels.

  • Deutsche Bank's downwardly revised outlook on AIG has the shares 0.7% lower before the open. The brokerage firm cut its assessment on the stock to "hold" from "buy," even though AIG has outperformed the S&P 500 Index (SPX) by almost 11 percentage points in the past three months, and yesterday touched a multi-year high of $63.70 before settling at $62.57. Still, short-term option traders are more put-heavy than usual. American International Group Inc's Schaeffer's put/call open interest ratio (SOIR) comes in at 1.46, revealing put open interest among options expiring in the next three months greatly outweighs call open interest. Plus, this reading marks an annual put-skewed extreme. 

  • AAVL is getting annihilated in pre-market action, poised to surrender nearly half its value -- and explore all-time lows -- after the company reported disappointing trial results for its experimental eye therapy. Even before this potentially huge bear gap, Avalanche Biotechnologies Inc was down 28% in 2015 at $38.88. Now, analysts are jumping on the bearish wagon, as SunTrust Robinson and William Blair each lowered their ratings to the equivalent of "neutral." Plus, the former more than halved its price target to $25. There's a good chance this isn't the last batch of bearish brokerage attention for AAVL: five of six analysts consider it was a "strong buy."
 
 

Which of These SUB-$5 Stocks Could 26x From Here? (AD)

He called a rare 11x on Tesla…

Then he called a 26x on Workhorse…

Then an even rarer 35x on Nio Inc…

Now Tim Bohen says these 5 tiny “America First” stocks are next up in 2025.

They’re trading for less than $5 right now.

But thanks to Elon & Trump’s new alliance…

They could be off to the races in Trump’s first 100 days.

And right now for a limited time…

You can get the names & tickers for just $1 here. (AD)

10 Stock Picks FREE
 
 

Featured Articles from Trusted Partners:

🚀 One Stock Pick Could Change Everything in 2025
What if one stock pick could define your success next year? Get 10 expert-vetted stocks set for 2025—plus 5 bonus picks to watch now. Get the Report →

🆕 New Options Need New Trading Strategies
Zero-DTE options are the newest (and hottest) options to trade.  Professional traders have rushed into the market and are making a mint.  Don’t get left behind - learn all about these options, how to trade them, market setups to profit from, plus much more. Download now →

👀 Revealed: 3 Defensive Stocks for Your Portfolio
Worried about the market? This free report reveals 3 under-the-radar defensive stocks for uncertain times in any kind of economy.

 

 
 

FREE Report Download

 

Follow us on X, Follow us on Twitter